Phase II study of Carboplatin and alternate-day administrations of TS-1 in patients with advanced squamous cell lung cancer.
Phase 2
Recruiting
- Conditions
- Squamous cell carcinoma of the lung
- Registration Number
- JPRN-UMIN000009308
- Lead Sponsor
- Kyoto Thoracic Oncology Research Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 35
Inclusion Criteria
Not provided
Exclusion Criteria
1.Contraindication of TS-1, CBDCA 2)Patients received adjuvant chemotherapy 3.Pregnant females, possibly pregnant females, females wishing to become pregnant and nursing mothers. Males that are currently attempting to produce a pregnancy 4.Active infection 5.HBs antigen positive 6.Severe complications, such as ileus, heart failure and renal failure 7.Continuous diarrhea 8.Massive pleural effusion and ascites 9.Active concomitant malignancy 10.Patients under treatment with flucytosine, phenytoin or warfarin potassium 11.Patients under treatment with steroids 12.Inadequate physical condition, as diagnosed by primary physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method